细胞分裂1蛋白调节因子在消化系统肿瘤治疗中的指导价值

肝癌电子杂志 ›› 2024, Vol. 11 ›› Issue (4): 27-35.

细胞分裂1蛋白调节因子在消化系统肿瘤治疗中的指导价值

刘一锋¹, 冉义洪^2,*, 车旭²

1.成都市第一人民医院胃肠外科,四川成都 610000;
2.国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院深圳医院肝胆外科,广东深圳 518116

收稿日期:2024-06-04 出版日期:2024-12-30 发布日期:2025-02-25
通讯作者: ^*冉义洪,E-mail：ranyihong5@163.com
基金资助:
深圳市“医疗卫生三名工程”项目（SZSM202011010）

Exploration of the guiding significance of protein regulating cytokinesis 1 in the management of gastrointestinal tumors

Liu Yifeng¹, Ran Yihong^2,*, Che Xu²

1. Department of Gastrointestinal Surgery, Chengdu First People's Hospital, Chengdu 610000, Sichuan, China;
2. Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, Guangzhou, China

Received:2024-06-04 Online:2024-12-30 Published:2025-02-25
Contact: ^*Ran Yihong, E-mail: ranyihong5@163.com

摘要/Abstract

摘要： 目的: 运用生物信息学工具分析细胞分裂1蛋白调节因子（protein regulating cytokinesis 1, PRC1）在消化系统肿瘤中的表达情况、生物学功能及其对患者预后的影响。
方法: 基于公共数据库分析PRC1在消化系统肿瘤中的表达量、共表达基因与生物学作用机制、免疫学调控特点及基因突变位点阐释,评估PRC1基因突变对消化系统肿瘤预后的影响。
结果: PRC1在胆管癌、结肠癌、肝癌、胰腺癌、直肠癌、胃癌中均高表达,且PRC1权重基因高度共表达,共同影响消化系统肿瘤的生物学进程。PRC1和权重基因集在基因本体（gene ontology, GO）富集分析中主要富集在有丝分裂相关条目。在免疫促癌方面,PRC1在胃癌和胰腺癌中对B细胞、CD4⁺T细胞、CD8⁺T细胞等免疫细胞发挥调控作用。PRC1以深度缺失、浅缺失、二倍体突变、扩增等多种突变形式影响消化系统肿瘤的生物学过程。PRC1片段上各位点以错义突变、截短为主要突变形式影响PRC1的翻译表达,进而影响消化系统肿瘤的生物学过程。PRC1高表达影响胃癌、胰腺癌的预后,PRC1突变预示消化系统肿瘤患者预后不良。
结论: PRC1在消化系统肿瘤中的高表达及突变是导致消化系统肿瘤进展和影响患者预后的高风险因素,研究PRC1及突变将进一步指导临床治疗工作。

关键词: 细胞分裂1蛋白调节因子, 消化系统肿瘤, 生物信息学, 治疗

Abstract: Objective: Analyzing the expression, biological role, and prognostic impact of protein regulating cytokinesis 1 (PRC1) in gastrointestinal tumors through bioinformatics tools, and subsequently guide clinical treatment.
Method: Based on a public database analysis, the expression level of PRC1 in gastrointestinal tumors, co-expressed genes, biological mechanisms of action, immunological regulatory characteristics, interpretation of gene mutation sites, prognostic impact on various tumors, and the prognostic impact of gene mutations on gastrointestinal tumors are analyzed.
Result: PRC1 was highly expressed in cholangiocarcinoma, colon cancer, liver cancer, pancreatic cancer, rectal cancer, and gastric cancer, and highly co-expressed with PRC1 related genes, which together affected the biological process of gastrointestinal tumors. The PRC1 and related gene sets were mainly enriched in mitotic related items in gene ontology (GO) enrichment analysis. In terms of immune promotion, PRC1 plays a regulatory role in B, CD4⁺, CD8⁺ and other immune cells in gastric and pancreatic cancer. PRC1 affects the biological process of gastrointestinal tumors in various forms of deep deletion, shallow deletion, diploid mutation, and amplification. The main mutation forms of each point on the PRC1 segment are missense mutations and truncations, which affect the translation and expression of PRC1, thereby affecting the biological process of gastrointestinal tumors. The high expression of PRC1 affects the prognosis of gastric cancer and pancreatic cancer. PRC1 mutation group indicates a poor prognosis of gastrointestinal tumors.
Conclusion: The high expression and mutation of PRC1 in gastrointestinal tumors are high-risk factors for malignant progression and poor prognosis of gastrointestinal tumors, further guiding clinical treatment strategies.

Key words: Protein regulating cytokinesis 1, Gastrointestinal tumor, Bioinformatic, Treatment

刘一锋, 冉义洪, 车旭. 细胞分裂1蛋白调节因子在消化系统肿瘤治疗中的指导价值[J]. 肝癌电子杂志, 2024, 11(4): 27-35.

Liu Yifeng, Ran Yihong, Che Xu. Exploration of the guiding significance of protein regulating cytokinesis 1 in the management of gastrointestinal tumors[J]. Electronic Journal of Liver Tumor, 2024, 11(4): 27-35.

参考文献

[1] CAO Y, HE H, LI R, et al.Latency-associated peptide identifies immunoevasive subtype gastric cancer with poor prognosis and inferior chemotherapeutic responsiveness[J]. Ann Surg, 2022, 275(1): e163-e173.
[2] WU D, ZHANG P, MA J, et al.Serum biomarker panels for the diagnosis of gastric cancer[J]. Cancer Med, 2019, 8(4): 1576-1583.
[3] PESSOA LS, HERINGER M, FERRER VP. ctDNA as a cancer biomarker: a broad overview[J]. Crit Rev Oncol Hematol, 2020, 155: 103109.
[4] LI J, DALLMAYER M, KIRCHNER T, et al.PRC1: linking cytokinesis, chromosomal instability, and cancer evolution[J]. Trends Cancer, 2018, 4(1): 59-73.
[5] VAN WIJNEN A J, BAGHERI L, BADRELDIN A A, et al. Biological functions of chromobox (CBX) proteins in stem cell self-renewal, lineage-commitment, cancer and development[J]. Bone, 2021, 143: 115659.
[6] HE Q, YANG J, JIN Y. Immune infiltration and clinical significance analyses of the coagulation-related genes in hepatocellular carcinoma[J]. Brief Bioinform, 2022, 23(4): bbac291.
[7] TANG Z, LI C, KANG B, et al.GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic Acids Res, 2017, 45(W1): W98-W102.
[8] WONG A K, PARK C Y, GREENE C S, et al.IMP: a multi-species functional genomics portal for integration, visualization and prediction of protein functions and networks[J]. Nucleic Acids Res, 2012, 40(Web Server issue): W484-W490.
[9] EVANGELISTA J E, XIE Z, MARINO G B, et al.Enrichr-KG: bridging enrichment analysis across multiple libraries[J]. Nucleic Acids Res, 2023, 51(W1): W168-W179.
[10] LI T, FAN J, WANG B, et al.TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells[J]. Cancer Res, 2017, 77(21): e108-e110.
[11] GAO J, AKSOY B A, DOGRUSOZ U, et al.Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal[J]. Sci Signal, 2013, 6(269): pl1.
[12] CAO T, PAN W, SUN X, et al.Increased expression of TET3 predicts unfavorable prognosis in patients with ovarian cancer-a bioinformatics integrative analysis[J]. J Ovarian Res, 2019, 12(1): 101.
[13] ANTONOWICZ S, REDDY S, SGROMO B. Gastrointestinal side effects of upper gastrointestinal cancer surgery. Best practice & research[J]. Clin Gastroenterol, 2020, 48-49: 101706.
[14] VAN DIJK S M, HEERKENS H D, TSENG D S J, et al. Systematic review on the impact of pancreatoduodenectomy on quality of life in patients with pancreatic cancer[J]. HPB (Oxford), 2018, 20(3): 204-215.
[15] PATEL T H, CECCHINI M.Targeted therapies in advanced gastric cancer[J]. Curr Treat Options Oncol, 2020, 21(9): 70.
[16] ROLFO C, BRONTE G, SORTINO G, et al.The role of targeted therapy for gastrointestinal tumors[J]. Expert Rev Gastroenterol Hepatol, 2014, 8(8): 875-885.
[17] ERMAN M. Molecular mechanisms of signal transduction: epidermal growth factor receptor family, vascular endothelial growth factor family, Kit, platelet-derived growth factor receptor, Ras[J]. J BUON, 2007, 12 Suppl 1: S83-S94.
[18] HAMADEH H K, TODD M, HEALY L, et al.Application of genomics for identification of systemic toxicity triggers associated with VEGF-R inhibitors[J]. Chem Res Toxicol, 2010, 23(6): 1025-1033.
[19] RENHOWE P A.Inhibitors of growth factor receptor kinase-dependent signaling pathways in anticancer chemotherapy--clinical progress[J]. Curr Opin Drug Discov Devel, 2002, 5(2): 214-224.
[20] GIL J, O'LOGHLEN A. PRC1 complex diversity: where is it taking us?[J]. Trends Cell Biol, 2014, 24(11): 632-641.
[21] LI X H, JU J Q, PAN Z N, et al.PRC1 is a critical regulator for anaphase spindle midzone assembly and cytokinesis in mouse oocyte meiosis[J]. FEBS J, 2021, 288(9): 3055-3067.
[22] CHEN G, YU M, CAO J, et al.Identification of candidate biomarkers correlated with poor prognosis of breast cancer based on bioinformatics analysis[J]. Bioengineered, 2021, 12(1): 5149-5161.
[23] ZHANG H, ZHOU D, ZHU F, et al.Disordered APC/C-mediated cell cycle progression and IGF1/PI3K/AKT signalling are the potential basis of Sertoli cell-only syndrome[J]. Andrologia, 2019, 51(7): e13288.
[24] SCHERÜBL H. Type-2-diabetes and gastrointestinal cancer screening[J]. Z Gastroenterol, 2023, 61(6): 683-689.
[25] WOOD S L, PERNEMALM M, CROSBIE P A, et al.The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets[J]. Cancer Treat Rev, 2014, 40(4): 558-566.
[26] MAO X, XU J, WANG W, et al.Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives[J]. Mol Cancer, 2021, 20(1): 131.